- Home
- CISS vs MYNZ Comparison
CISS vs MYNZ Comparison
Compare CISS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- MYNZ
- Stock Information
- Founded
- CISS 2022
- MYNZ 2021
- Country
- CISS Greece
- MYNZ Germany
- Employees
- CISS N/A
- MYNZ N/A
- Industry
- CISS Marine Transportation
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- MYNZ Health Care
- Exchange
- CISS Nasdaq
- MYNZ Nasdaq
- Market Cap
- CISS 2.8M
- MYNZ 5.5M
- IPO Year
- CISS N/A
- MYNZ 2021
- Fundamental
- Price
- CISS $3.28
- MYNZ $1.44
- Analyst Decision
- CISS
- MYNZ Buy
- Analyst Count
- CISS 0
- MYNZ 2
- Target Price
- CISS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CISS 120.9K
- MYNZ 117.3K
- Earning Date
- CISS 08-21-2025
- MYNZ 07-15-2025
- Dividend Yield
- CISS N/A
- MYNZ N/A
- EPS Growth
- CISS N/A
- MYNZ N/A
- EPS
- CISS N/A
- MYNZ N/A
- Revenue
- CISS $38,174,754.00
- MYNZ $893,991.00
- Revenue This Year
- CISS N/A
- MYNZ $26.06
- Revenue Next Year
- CISS N/A
- MYNZ $4.97
- P/E Ratio
- CISS N/A
- MYNZ N/A
- Revenue Growth
- CISS N/A
- MYNZ N/A
- 52 Week Low
- CISS $2.85
- MYNZ $1.34
- 52 Week High
- CISS $23.25
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- CISS 41.98
- MYNZ 26.61
- Support Level
- CISS $3.06
- MYNZ $1.35
- Resistance Level
- CISS $4.00
- MYNZ $1.46
- Average True Range (ATR)
- CISS 0.39
- MYNZ 0.12
- MACD
- CISS -0.03
- MYNZ 0.02
- Stochastic Oscillator
- CISS 16.42
- MYNZ 9.27
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.